TREGZI Wins FDA Approval, Moving Blood Cancer Transplantation Into an Era of Precision Tuning of Cell Composition

For many patients with high-risk blood cancers, allogeneic hematopoietic stem cell transplantation is often an important path toward long-term remission, but it can also bring another chronic disease into their lives. The U.S. FDA has approved TREGZI for adult patients with hematologic malignancies who are receiving hematopoietic stem cell transplantation from a matched donor and myeloablative conditioning, pushing the focus of transplant medicine further from “whether engraftment is possible” to “how to rebuild a more stable immune order.”

TREGZI, clinically known as Orca-T, is an immune cell product based on allogeneic regulatory T cells and combined with hematopoietic stem cells and T cells. Unlike traditional transplantation, which is closer to infusing donor cells as a “whole package,” this therapy separates hematopoietic stem/progenitor cells, regulatory T cells, conventional T cells, and diluent into four infusion bags, prepared according to the patient and donor sources. The aim is to preserve the graft-versus-leukemia effect while reducing the long-term burden of graft-versus-host disease.

The FDA approval is based on the randomized, multicenter phase 3 Precision-T trial. Data released by Orca Bio show that the trial enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and mixed phenotype acute leukemia; at 12 months, chronic GVHD-free event-free survival was 78% in the TREGZI group and 38% in the traditional allogeneic transplant group. The incidence of chronic GVHD was 13% and 44%, respectively, while overall survival was 94% and 83%.

These figures carry clinical weight because chronic GVHD is not a transient side effect. It can affect the skin, mouth, eyes, liver, lungs, and joints, leaving transplant survivors dependent on immunosuppressive therapy over the long term and increasing the risks of infection and impaired daily function. However, the publicly available data mainly come from company press releases, prescribing information, and trial summaries; experience across different transplant centers, real-world accessibility, and long-term follow-up will still determine whether this therapy can move from approval to stable use.

The prescribing information also warns that TREGZI has not eliminated the core risks of transplantation itself. The label lists warnings including graft failure, acute or chronic GVHD, infusion reactions, secondary malignancies or donor-derived malignancies, and transmission of infectious pathogens. Common adverse reactions include mucositis, diarrhea, rash, viral or bacterial infection, abdominal pain, vomiting, bleeding, edema, and fungal infection; this makes it more like a transplant platform requiring management by a highly specialized team than an alternative that simplifies the transplant process.

Background Context

In recent years, cell therapies have mostly entered public view through the narrative of “enhanced attack,” such as CAR-T; the significance of TREGZI lies at the other end: it attempts to use regulatory T cells to rearrange the brakes and accelerator of the immune response. If subsequent data can support sustained efficacy, stable manufacturing, and cost control, the standards for evaluating blood cancer transplantation may no longer look only at relapse and early mortality, but may also more seriously incorporate patients’ immune-related quality of life one year, three years, or even longer after transplantation.